A 2-part, Cross-over Trial of NOMAC-E2 to Assess Bioequivalence Between the Phase 3 Pivotal Clinical Batches and a Batch Prepared Using the Commercial Drug Manufacturing Process

Trial Profile

A 2-part, Cross-over Trial of NOMAC-E2 to Assess Bioequivalence Between the Phase 3 Pivotal Clinical Batches and a Batch Prepared Using the Commercial Drug Manufacturing Process

Completed
Phase of Trial: Phase I

Latest Information Update: 06 Oct 2014

At a glance

  • Drugs Estradiol/nomegestrol (Primary)
  • Indications Postmenopausal osteoporosis
  • Focus Pharmacokinetics
  • Sponsors Merck Sharp & Dohme; Schering-Plough
  • Most Recent Events

    • 06 May 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top